Trial reportToxins2016
Incobotulinum Toxin-A Improves Post-Surgical and Post-Radiation Pain in Cancer Patients.
Trial report in Toxins, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03571334 (Botulinum Toxin A for the Treatment of Chemotherapy Induced Peripheral Neuropathy), which is not on this map. Cited by 18 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Botulinum Toxin A for the Treatment of Chemotherapy Induced Peripheral Neuropathy
Who cites it
18 citing papers in PubMed, 3 syntheses or guidelines pooled it, 40 citations in OpenAlex.
- Pooled it
- Botulinum Toxin for Pain Relief in Cancer Patients: A Systematic Review of Randomized Controlled Trials.Toxins · 2024Pooled it
- Pooled it
- The Esthetic Use of Botulinum Toxins in Cancer Patients: Providing a Foundation for Future Indications.Toxins · 2025Review
- Intra- and Postoperative Botulinum Toxin Injection in Postsurgical Pain Management: A Literature Review.Pain research & management · 2025Review
- The efficacy of botulinum toxin in neuropathic pain: a systematic review.British journal of pain · 2024Article
- Targeting TRPV4 Channels for Cancer Pain Relief.Cancers · 2024Review
- Cancer Pain Management: A Narrative Review of Current Concepts, Strategies, and Techniques.Current oncology (Toronto, Ont.) · 2023Review
- A Review on the Management of Peripheral Neuropathic Pain Following Breast Cancer.Breast cancer (Dove Medical Press) · 2023Review
- Do Bacteria Provide an Alternative to Cancer Treatment and What Role Does Lactic Acid Bacteria Play?Microorganisms · 2022Review
- Botulinum toxin in cancer therapy-current perspectives and limitations.Applied microbiology and biotechnology · 2022Review
- Mobilizing Toxins for Cancer Treatment: Historical Perspectives and Current Strategies.Toxins · 2020Article
- A Comprehensive Review of the Diagnosis, Treatment, and Management of Postmastectomy Pain Syndrome.Current pain and headache reports · 2020Review
- Review
- Botulinum Neurotoxin for the Treatment of Neuropathic Pain.Frontiers in neurology · 2020Review
- Botulinum neurotoxin type A for the treatment of pain: not just in migraine and trigeminal neuralgia.The journal of headache and pain · 2017Review
- Review
- Ultrasound-Guided Dry Needling As a Treatment For Postmastectomy Pain Syndrome - A Case Series of Twenty Patients.Indian journal of palliative careArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer patients who undergo surgery or radiation can develop persistent focal pain at the site of radiation or surgery. Twelve patients who had surgery or radiation for local cancer and failed at least two analgesic medications for pain control were prospectively enrolled in a research protocol. Patients were injected up to 100 units of incobotulinum toxin A (IncoA) intramuscularly or subcutaneously depending on the type and location of pain (muscle cramp or neuropathic pain). Two patients passed away, one dropped out due to a skin reaction and another patient could not return for the follow up due to his poor general condition. All remaining 8 subjects (Age 31-70, 4 female) demonstrated significant improvement of Visual Analog Scale (VAS) (3 to 9 degrees, average 3.9 degrees) and reported significant satisfaction in Patients' Global Impression of Change scale (PGIC) (7 out of 8 reported the pain as much improved). Three of the 8 patients reported significant improvement of quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.